Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: XENE

Xenon Pharmaceuticals Inc.

Healthcare | Biotechnology

No licensed closing price on file for XENE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-4.74

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.

What Xenon Pharmaceuticals Inc. does

This company is a neuroscience-focused biopharmaceutical firm engaged in discovering, developing, and commercializing therapies for neurological and psychiatric disorders. The company's lead candidate, azetukalner, a potassium channel opener, is currently in Phase 3 clinical studies for epilepsy indications including focal onset seizures and primary generalized tonic-clonic seizures, as well as for major depressive disorder and bipolar depression. The early-stage pipeline includes other potassium channel openers and sodium channel modulators being studied for conditions such as pain.

Summarized from Xenon Pharmaceuticals Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-4.74

Revenue, margins & earnings

FY2021: net loss $79M on revenue $18M$18MFY2021FY2022: net loss $125M on revenue $9M$9MFY2022FY2025: net loss $346M on revenue $8M$8MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16Chief Financial OfficerOption exercise7,500—
  • 2026-10-16Chief Financial OfficerRestricted Share UnitsOption exercise-7,500—
  • 2026-10-01PRESIDENT & CEOPurchase30,000$1.12M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Xenon Pharmaceuticals Inc. do?

This company is a neuroscience-focused biopharmaceutical firm engaged in discovering, developing, and commercializing therapies for neurological and psychiatric disorders.

When did XENE last file with the SEC?

Xenon Pharmaceuticals Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-03. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:47 UTC. This page is also available as JSON at /api/data?ticker=XENE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for XENE and 5,000+ tickers.

Create a free account — keep XENE
For your agent
GET /api/data?ticker=XENE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt